579 related articles for article (PubMed ID: 33136431)
1. COVID-19 basics and vaccine development with a Canadian perspective.
Liu M; Chen X
Can J Microbiol; 2021 Feb; 67(2):112-118. PubMed ID: 33136431
[TBL] [Abstract][Full Text] [Related]
2. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
Russell RL; Pelka P; Mark BL
Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
[TBL] [Abstract][Full Text] [Related]
3. [SARS-CoV-2 vaccines].
Benfield TL; Helweg-Larsen J
Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
[TBL] [Abstract][Full Text] [Related]
4. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
5. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
Bennet BM; Wolf J; Laureano R; Sellers RS
Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
[TBL] [Abstract][Full Text] [Related]
6. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
[TBL] [Abstract][Full Text] [Related]
7. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
8. Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs.
Malone B; Simovski B; Moliné C; Cheng J; Gheorghe M; Fontenelle H; Vardaxis I; Tennøe S; Malmberg JA; Stratford R; Clancy T
Sci Rep; 2020 Dec; 10(1):22375. PubMed ID: 33361777
[TBL] [Abstract][Full Text] [Related]
9. The race for a COVID-19 vaccine.
Lavigne SE
Can J Dent Hyg; 2020 Oct; 54(3):107-109. PubMed ID: 33240370
[No Abstract] [Full Text] [Related]
10. Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets.
Oliveira SC; de Magalhães MTQ; Homan EJ
Front Immunol; 2020; 11():587615. PubMed ID: 33193414
[TBL] [Abstract][Full Text] [Related]
11. Deciphering Vaccines for COVID-19: where do we stand today?
Baviskar T; Raut D; Bhatt LK
Immunopharmacol Immunotoxicol; 2021 Feb; 43(1):8-21. PubMed ID: 33054486
[TBL] [Abstract][Full Text] [Related]
12. Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding.
Trimpert J; Dietert K; Firsching TC; Ebert N; Thi Nhu Thao T; Vladimirova D; Kaufer S; Labroussaa F; Abdelgawad A; Conradie A; Höfler T; Adler JM; Bertzbach LD; Jores J; Gruber AD; Thiel V; Osterrieder N; Kunec D
Cell Rep; 2021 Aug; 36(5):109493. PubMed ID: 34320400
[TBL] [Abstract][Full Text] [Related]
13. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
Yahalom-Ronen Y; Tamir H; Melamed S; Politi B; Shifman O; Achdout H; Vitner EB; Israeli O; Milrot E; Stein D; Cohen-Gihon I; Lazar S; Gutman H; Glinert I; Cherry L; Vagima Y; Lazar S; Weiss S; Ben-Shmuel A; Avraham R; Puni R; Lupu E; Bar-David E; Sittner A; Erez N; Zichel R; Mamroud E; Mazor O; Levy H; Laskar O; Yitzhaki S; Shapira SC; Zvi A; Beth-Din A; Paran N; Israely T
Nat Commun; 2020 Dec; 11(1):6402. PubMed ID: 33328475
[TBL] [Abstract][Full Text] [Related]
14. Efforts towards a COVID-19 vaccine.
Brüssow H
Environ Microbiol; 2020 Oct; 22(10):4071-4084. PubMed ID: 32893468
[TBL] [Abstract][Full Text] [Related]
15. Targets and strategies for vaccine development against SARS-CoV-2.
Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
[TBL] [Abstract][Full Text] [Related]
16. Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An
Dar HA; Waheed Y; Najmi MH; Ismail S; Hetta HF; Ali A; Muhammad K
J Immunol Res; 2020; 2020():8893483. PubMed ID: 33274246
[TBL] [Abstract][Full Text] [Related]
17. Natural and genetically-modified animal models to investigate pulmonary and extrapulmonary manifestations of COVID-19.
Tiwari S; Goel G; Kumar A
Int Rev Immunol; 2024; 43(1):13-32. PubMed ID: 35757923
[TBL] [Abstract][Full Text] [Related]
18. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 infection in patients with a normal or abnormal liver.
Cabibbo G; Rizzo GEM; Stornello C; Craxì A
J Viral Hepat; 2021 Jan; 28(1):4-11. PubMed ID: 33190321
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies.
Rawat K; Kumari P; Saha L
Eur J Pharmacol; 2021 Feb; 892():173751. PubMed ID: 33245898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
